| CTRI Number |
CTRI/2025/08/093290 [Registered on: 19/08/2025] Trial Registered Prospectively |
| Last Modified On: |
19/08/2025 |
| Post Graduate Thesis |
Yes |
| Type of Trial |
Interventional |
|
Type of Study
|
Drug Ayurveda |
| Study Design |
Randomized, Parallel Group, Active Controlled Trial |
|
Public Title of Study
|
Comparison of an Ayurvedic Polyherbal Syrup and Ondansetron Syrup for Vomiting (Chhardi) in Children of 1 year to 18 years |
|
Scientific Title of Study
|
Evaluation of the comparative efficacy of Polyherbal syrup versus Ondansetron syrup in the management of Chhardi(vomiting) in children: A Randomized Controlled Trial |
| Trial Acronym |
NIL |
|
Secondary IDs if Any
|
| Secondary ID |
Identifier |
| NIL |
NIL |
|
|
Details of Principal Investigator or overall Trial Coordinator (multi-center study)
|
| Name |
DR DHANANJAY BHAGWAN MORE |
| Designation |
PG SCHOLAR |
| Affiliation |
Mahatma Gandhi Ayurved College, Hospital and Research Centre, Salod(H) Wardha |
| Address |
Room No 41, Department of Kaumarbhritya, Mahatma Gandhi Ayurved College, Hospital and Research Centre Salod Hirapur Wardha
MAHARASHTRA
442001 India
Wardha
MAHARASHTRA
Wardha MAHARASHTRA 442001 India |
| Phone |
8956125085 |
| Fax |
|
| Email |
moredhananjay002@gmail.com |
|
Details of Contact Person Scientific Query
|
| Name |
DR RENU B RATHI |
| Designation |
PROFESSOR AND HOD |
| Affiliation |
Mahatma Gandhi Ayurved College, Hospital and Research Centre Salod(H) Wardha |
| Address |
Room No 41, Department of Kaumarbhritya, Mahatma Gandhi Ayurved College, Hospital and Research Centre Salod Hirapur Wardha
MAHARASHTRA
442001 India
Wardha
MAHARASHTRA
Wardha MAHARASHTRA 442001 India |
| Phone |
9011058302 |
| Fax |
|
| Email |
rbr.226@gmail.com |
|
Details of Contact Person Public Query
|
| Name |
DR DHANANJAY BHAGWAN MORE |
| Designation |
PG SCHOLAR |
| Affiliation |
Mahatma Gandhi Ayurved College, Hospital and Research Centre Salod(H) Wardha |
| Address |
Room No 41, Department of Kaumarbhritya, Mahatma Gandhi Ayurved College, Hospital and Research Centre Salod Hirapur Wardha
MAHARASHTRA
442001 India
Wardha
MAHARASHTRA
Wardha MAHARASHTRA 442001 India |
| Phone |
8956125085 |
| Fax |
|
| Email |
moredhananjay002@gmail.com |
|
|
Source of Monetary or Material Support
|
| Mahatma Gandhi Ayurved College, Hospital and Research Centre Salod, Hirapur, Wardha, Maharashtra, India 442001 |
|
|
Primary Sponsor
|
| Name |
Mahatma Gandhi Ayurved College, Hospital and Research Centre |
| Address |
Room No 41, Department of Kaumarbhritya, Mahatma Gandhi Ayurved College, Hospital and Research Centre Salod(H) Wardha.
MAHARASHTRA
442001 India
Wardha
MAHARASHTRA |
| Type of Sponsor |
Research institution and hospital |
|
|
Details of Secondary Sponsor
|
|
|
Countries of Recruitment
|
India |
|
Sites of Study
|
| No of Sites = 1 |
| Name of Principal
Investigator |
Name of Site |
Site Address |
Phone/Fax/Email |
| DR DHANANJAY BHAGWAN MORE |
Mahatma Gandhi Ayurved College, Hospital and Research Centre |
Room No 41, Department of Kaumarbhritya, Mahatma Gandhi Ayurved College, Hospital and Research Centre Salod Hirapur Wardha.
MAHARASHTRA
442001 India
Wardha
MAHARASHTRA Wardha MAHARASHTRA |
8956125085
moredhananjay002@gmail.com |
|
|
Details of Ethics Committee
|
| No of Ethics Committees= 1 |
| Name of Committee |
Approval Status |
| Mahatma Gandhi Ayurved College Hospital and Research Centre Institutional Committee |
Approved |
|
|
Regulatory Clearance Status from DCGI
|
|
|
Health Condition / Problems Studied
|
| Health Type |
Condition |
| Patients |
(1) ICD-10 Condition:R111||Vomiting. Ayurveda Condition: CARDIH, |
|
|
Intervention / Comparator Agent
|
| sno | Intervention/Comparator | Type | Drug-Type | Procedure Name | Details | | 1 | Intervention Arm | Drug | Classical | | (1) Medicine Name: Polyherbal Syrup, Reference: 1) Priyangwadi Kalka Referance-Bhaishajya Ratnavali Chapter 71/46 2) Shunthi Referance- Bhavprakash Nighantu Haritakyadi Varga 3) Ela Referance- Bhavprakash Nighantu Karpuradi Varga, Route: Oral, Dosage Form: Sharkara/ Syrup, Dose: 5(ml), Frequency: tds, Bhaishajya Kal: Pragbhakta, Duration: 5 Days, anupAna/sahapAna: No, Additional Information: In the formulation of a polyherbal syrup, I have incorporated Priyangwadi Kalka as described in Bhaishajya Ratnavali, Chapter 71, verse 46, for the treatment of Chhardi (vomiting) in children, To enhance the antiemetic effect of this Kalka, I have added Shunthi and Ela, both of which are referenced for their antiemetic properties in Bhavaprakash Nighantu—Shunthi under the Haritakyadi Varga and Ela under the Karpuradi Varga | | 2 | Comparator Arm (Non Ayurveda) | | - | Ondansetron Syrup | Ondansetron is a selective 5-HT₃ receptor antagonist.
Mechanism of action: It works by blocking serotonin receptors (5-HT₃) in both the central nervous system and the gastrointestinal (GI) tract, which prevents the transmission of signals that cause nausea and vomiting. In the GI tract, serotonin release during chemotherapy, radiation, or other stimuli triggers vomiting. Ondansetron prevents this action by inhibiting serotonin’s interaction with its 5-HT₃ receptor. – In the brain, it blocks the chemoreceptor trigger zone (CTZ), which helps to reduce nausea and vomiting.
|
|
|
|
Inclusion Criteria
|
| Age From |
1.00 Year(s) |
| Age To |
18.00 Year(s) |
| Gender |
Both |
| Details |
1)Written informed Consent and ascent will be obtain
2)Age 1 year to 18 years
3)3 or more than 3 episodes of vomiting in 24 hours
4)Mild to moderate dehydration
5)Associated diarrhea patients will also be included |
|
| ExclusionCriteria |
| Details |
1)Moderate to Severe infection and dehydration or shock
2)Any Chronic systemic illness
3)Antiemetic use in the past 24 hours
4)Allergy to any formulation ingredient
5)Fever more than 100 degree fahrenheit
6)Abuse, poison or suspicious case
7)Congenital anomalies and Metabolic syndrome
8)Participants did not receive the Antihelminthic drug |
|
|
Method of Generating Random Sequence
|
Computer generated randomization |
|
Method of Concealment
|
Pre-numbered or coded identical Containers |
|
Blinding/Masking
|
Participant and Investigator Blinded |
|
Primary Outcome
|
| Outcome |
TimePoints |
| To assess the efficacy of Polyherbal Syrup in the management of chhardi in children of age 1 year to 18 years with objective and subjective criteria |
Assessment daily for 5 days and post-treatment follow-up on 7th,10th, and
14th day |
|
|
Secondary Outcome
|
| Outcome |
TimePoints |
| To assess the efficacy of Ondansetron Syrup in the management of chhardi in children with objective and subjective criteria. |
Assessment daily for 5 days and post-treatment follow-up on 7th,10th, and
14th day |
|
|
Target Sample Size
|
Total Sample Size="108" Sample Size from India="108"
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" |
|
Phase of Trial
|
Phase 3/ Phase 4 |
|
Date of First Enrollment (India)
|
10/10/2025 |
| Date of Study Completion (India) |
Applicable only for Completed/Terminated trials |
| Date of First Enrollment (Global) |
Date Missing |
| Date of Study Completion (Global) |
Applicable only for Completed/Terminated trials |
|
Estimated Duration of Trial
|
Years="2" Months="0" Days="0" |
|
Recruitment Status of Trial (Global)
|
Not Yet Recruiting |
| Recruitment Status of Trial (India) |
Not Yet Recruiting |
|
Publication Details
|
N/A |
|
Individual Participant Data (IPD) Sharing Statement
|
Will individual participant data (IPD) be shared publicly (including data dictionaries)?
Response - NO
|
|
Brief Summary
|
The volunteers will be informed about the study protocol. Willing participants will be randomly selected from per computer-generated table. The clinical research format will be prepared and validated. Before the study approval is taken from IEC, MGACHRC, Salod (H) Wardha, and CTRI registration will be done. After selection, each participant will be tested individually and selected according to the selection criteria. They are divided into two groups. The trial is a Randomized, double-blind, equivalence Clinical Trial. Assessment daily for 5 days and post-treatment follow-up on 7th,10th, and 14th day. |